慢阻肺月报202206
慢阻肺月报202206
American Journal of Respiratory and Critical Care Medicine. 2022 Jun 1; PMID: 35649189
Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative LEEP Trial.
Robert A Wise, Janet T Holbrook, Robert H Brown, et al
American Lung Association Airways Clinical Research Centers and Pulmonary Trials Cooperative
American Journal of Respiratory and Critical Care Medicine. 2022 May 12; PMID: 35549640
Reversible Airflow Obstruction Predicts Future COPD Development in the SPIROMICS Cohort.
Russell G Buhr, Igor Z Barjaktarevic, P Miguel Quibrera, et al
这项研究说明支扩剂前FEV1/FVC<0.70(但支扩剂后≥0.70)者之后发展支扩剂后FEV1/FVC<0.70的风险很大(符合GOLD 2022提出的慢阻肺前期)。这部分人群呼吸道症状的发生率更高，肺气肿更显著，肺功能也更差且下降速度更快。因此，有必要加以关注，并且研究者认为在慢阻肺的肺功能诊断标准中需要考虑支扩剂前的测定结果。
Journal of Allergy and Clinical Immunology. 2022 May 25; PMID: 35643377
Airway and parenchymal transcriptomics in a novel model of asthma and COPD overlap.
Xiaofan Tu, Richard Y Kim, Alexandra C Brown, et al
American Journal of Respiratory and Critical Care Medicine. 2022 May 12; PMID: 35549656
Increased SARS-CoV-2 Infection, Protease and Inflammatory Responses in COPD Primary Bronchial Epithelial Cells Defined with Single Cell RNA-Sequencing.
Matt D Johansen, Rashad M Mahbub, Sobia Idrees, et al
该研究给出了慢阻肺患者对新冠病毒更易感的实验证据，并且找到产生保护性免疫应答的关键细胞。
相关文章
评论
我要跟帖
